# South Korea Anti VEGF Market

> South Korea Anti-VEGF Market Research Report: Size, Share, Trend Analysis By Product (Eylea, Lucentis, Beovu) and By Disease (Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-Related Macular Degeneration) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 4.3%
- **2024:** $ 649.6 Million
- **2025:** $ 677.53 Million
- **2035:** $ 1,032.45 Million
- **Key Players:** Regeneron Pharmaceuticals (US), Roche Holding AG (CH), Novartis AG (CH), Bayer AG (DE), Pfizer Inc. (US), Amgen Inc. (US), Eli Lilly and Company (US), Santen Pharmaceutical Co., Ltd. (JP)

**Report ID:** MRFR/HC/50407-HCR · **Pages:** 200 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** April 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/south-korea-anti-vegf-market-52165

---

## Market Summary

## **South Korea Anti-VEGF Market Overview:**

As per MRFR analysis, the South Korea Anti-VEGF Market Size was estimated at 622.72 (USD Million) in 2023. The South Korea Anti-VEGF Market Industry is expected to grow from 649.5(USD Million) in 2024 to 1,054.8 (USD Million) by 2035. The South Korea Anti-VEGF Market CAGR (growth rate) is expected to be around 4.507% during the forecast period (2025 - 2035).

### **Key South Korea Anti-VEGF Market Trends Highlighted**

The South Korea Anti-VEGF market is undergoing significant trends as a result of the growing prevalence of eye diseases, particularly age-related macular degeneration and diabetic retinopathy.. The demand for anti-VEGF therapies is on the rise as a result of the increasing elderly population and the increasing number of individuals seeking treatment solutions. The government is actively promoting the development and approval of innovative treatment options, promoting the creation of rapid pathways that facilitate the timely access to novel therapies.

There is a substantial effort to advance drug delivery systems and personalized medicine, which is consistent with the global trend towards more effective and targeted treatments. Local biotech firms and pharmaceutical companies, particularly those that concentrate on the development of biosimilars to existing anti-VEGF medicines, have numerous opportunities. The regulatory environment in South Korea is conducive to innovation, and the potential for novel therapies to penetrate the market creates a significant opportunity for growth.

Academic institutions and enterprises are collaborating to promote research that has the potential to result in new therapies and discoveries, thereby improving the treatment options available in the market. The introduction of combination therapies, which combine anti-VEGF medications with other treatments to improve efficacy, has caused a shift in market dynamics in recent years. This trend is indicative of the increasing recognition of the intricacy of ocular diseases and the necessity of comprehensive treatment strategies.

Furthermore, healthcare organizations implement awareness campaigns to educate both practitioners and patients regarding the advantages of early diagnosis and treatment, which are essential for the effective management of ocular diseases in South Korea.

Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review**

## **South Korea Anti-VEGF Market Drivers**

### Increasing Prevalence of Age-Related Macular Degeneration

The South Korea Anti-VEGF Market Industry is largely driven by the increasing prevalence of age-related macular degeneration (AMD). According to the Korean National Health Insurance Service, approximately 1.5 million South Koreans are diagnosed with AMD each year, a figure that has been progressively increasing. The growing elderly population, expected to constitute more than 20% of the South Korean population by 2025, underscores the urgent need for effective treatments. As such, anti-VEGF therapies, which have shown efficacy in slowing the progression of AMD, are increasingly being adopted in clinical practice.

This surge in demand for anti-VEGF treatments is bolstered by healthcare initiatives aimed at enhancing the healthcare system and increasing access to novel therapies. Renowned organizations such as the Korean Ophthalmological Society are actively promoting early diagnosis and treatment, further stimulating market growth.

### Innovative Product Development

Ongoing innovations in the anti-VEGF segment are substantially influencing the South Korea Anti-VEGF Market Industry. Recent launches of novel anti-VEGF agents, such as newer formulations with enhanced efficacy profiles, are becoming more common due to Research and Development initiatives by pharmaceutical companies.
 For example, significant investments in Research and Development by companies such as Samsung Bioepis and Hanmi Pharmaceutical have resulted in new treatment options that cater to the unique needs of South Korean patients.The South Korean government has also been offering incentives to promote biopharmaceutical innovation, making it more feasible for companies to develop cutting-edge solutions.

### Government Initiatives and Favorable Healthcare Policies

The South Korean government has been formulating favorable healthcare policies aimed at improving patient access to anti-VEGF treatments. The Health Insurance Review and Assessment Service has recently revised coverage policies to include advanced anti-VEGF treatments, effectively reducing out-of-pocket expenses for patients. This type of government intervention is crucial given that accessibility directly impacts treatment choices among patients suffering from retinal diseases.
The National Health Insurance system now recognizes the importance of timely intervention. It is adapting its policies to ensure that affordable treatment options are available to a broader population, consequently driving growth within the South Korea Anti-VEGF Market Industry.

### Rising Awareness and Screening Programs

Enhanced awareness about ocular diseases and the importance of early detection has significantly contributed to the growth of the South Korea Anti-VEGF Market Industry. Various non-profit organizations and health care institutions in South Korea have initiated screening programs to bring attention to the risks associated with eye diseases such as diabetic retinopathy and macular degeneration.

The Korean Diabetes Association, for example, has reported that nearly 30% of patients with diabetes have some form of diabetic retinopathy, emphasizing the need for regular screenings.These initiatives aim to educate the public about the availability of treatment options, thereby driving the demand for anti-VEGF therapies as more patients seek timely intervention.

## **South Korea Anti-VEGF Market Segment Insights:**

### **Anti-VEGF Market Product Insights**

The South Korea Anti-VEGF Market presents a robust landscape driven by a variety of products aimed at treating conditions like age-related macular degeneration and diabetic retinopathy. Among these products, Eylea has gained substantial traction due to its efficacy in improving vision outcomes and extended dosing intervals, allowing for a more manageable treatment regimen for patients. Similarly, Lucentis has established its place in this market through its targeted approach and trust built over years of clinical usage, making it a preferred choice among ophthalmologists.

Additionally, Beovu, a newer entrant in the South Korea Anti-VEGF Market, is noted for its ability to offer competitive treatment options that address unmet needs in visual health. This product segment is characterized by ongoing research and development aimed at improving existing treatments and developing novel approaches to combat retinal diseases. Government initiatives and increasing healthcare expenditures in South Korea further support the growth of the Anti-VEGF product segment, fostering an environment of innovation and access to advanced therapies.

The market trends indicate a significant shift towards personalized medicine, with healthcare providers being actively engaged in tailoring treatments to individual patient needs. This engagement has led to a more dynamic market, encouraging pharmaceutical companies to invest in new solutions that align with the evolving landscape of medical practice. Moreover, the South Korea Anti-VEGF Market is influenced by an aging population and a rising prevalence of chronic eye diseases, creating a heightened demand for effective treatment options. Overall, the diverse product offerings within this segment cater to varying patient needs, driving competition and fostering advancement in treatment methodologies.

Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review**

### **Anti-VEGF Market Disease Insights**

The South Korea Anti-VEGF Market, particularly in the Disease segment, exhibits significant relevance, especially considering the increasing prevalence of retinal diseases within the population. The market is characterized by conditions such as Macular Edema, which often results from diabetes and is crucial for vision health, dominating the landscape due to its growing incidence. Diabetic Retinopathy also holds considerable significance as a leading cause of vision loss among working-age adults, emphasizing the need for effective anti-VEGF therapies. Additionally, Retinal Vein Occlusion is a notable contributor to vision impairment, acting as a critical area of focus for healthcare providers.

Age-Related Macular Degeneration represents a substantial challenge in the aging South Korean demographic, leading to a rising demand for advanced treatments. Collectively, these conditions highlight the urgency for innovative interventions and healthcare strategies in the South Korea Anti-VEGF Market, driven by an aging population and lifestyle-related health concerns. The market dynamics reflect not just a response to the existing disease burden but also an opportunity for growth and advancement in ocular disease management.

### **South Korea Anti-VEGF Market Key Players and Competitive Insights:**

The South Korea Anti-VEGF Market is characterized by a robust competitive landscape driven by the increasing prevalence of retinal diseases and the demand for innovative therapies. Anti-VEGF agents are critical in treating conditions such as age-related macular degeneration, diabetic retinopathy, and other ocular disorders. The market is witnessing significant investments in research and development, resulting in the introduction of novel therapies aimed at improving patient outcomes. A shift towards personalized medicine and the growing acceptance of biologics in treatment protocols are shaping market dynamics, amplifying the competition among key players.

Additionally, regulatory frameworks and healthcare expenditures in South Korea are conducive to the growth of this market, further intensifying competition among manufacturers and biopharmaceutical companies.In South Korea, Regeneron Pharmaceuticals has established a strong foothold in the anti-VEGF sector, particularly with its flagship product designed for ocular conditions. The company's extensive clinical trial data and established efficacy have solidified its reputation among healthcare professionals and patients alike. Regeneron's strength lies in its commitment to innovation and robust pipeline of anti-VEGF therapies, which are continually being refined and optimized based on feedback from clinical practice.

The company's strategic collaborations with local healthcare systems and participation in clinical research further enhance its market presence, allowing it to maintain a competitive edge while responding to the specific needs of the South Korean population. Regeneron's ongoing engagement with physicians and healthcare providers ensures that its products remain at the forefront of treatment options available in the anti-VEGF market.Zymeworks has also made notable strides within the South Korea Anti-VEGF Market, particularly with its proprietary biologic platforms that enable the development of differentiated therapies.

The company's focus on creating innovative treatments tailored to meet specific patient needs bodes well for its presence in this competitive landscape. Zymeworks has embarked on strategic partnerships and has been active in pursuing mergers and acquisitions to bolster its development capabilities and expand its market reach. Notable products under its development pipeline cater to ocular diseases, with emphasis on enhancing the efficacy and safety profile compared to existing therapies.

Zymeworks' strategy involves leveraging its novel biotherapeutic platforms to push the boundaries of conventional anti-VEGF treatment and build a significant presence in the South Korean market, where patient-centric solutions continue to drive demand for advanced therapies.

### **Key Companies in the South Korea Anti-VEGF Market Include:**

## **South Korea Anti-VEGF Market Industry Developments**

The South Korea Anti-VEGF Market has shown significant activity in recent months, particularly with advancements involving prominent companies such as Regeneron Pharmaceuticals and Novartis. In September 2023, Regeneron obtained regulatory approval for its Eylea injection, aimed at treating various retinal diseases, which marks a crucial development for the regional market. In addition, Zymeworks has been expanding its pipeline, focusing on anti-VEGF therapies, which has garnered attention among local investors. Companies like Amgen and Pfizer continue to enhance their portfolios in this space, with ongoing Research and Development efforts that align with South Korea's advanced healthcare infrastructure.

Furthermore, recent months have seen considerable mergers and acquisitions, notably Santen Pharmaceutical's acquisition of a local firm to bolster its anti-VEGF portfolio in May 2023. The surge in market valuation has led to heightened competition, with Roche and AbbVie increasing their research capabilities and developing innovative strategies to capture a larger share. The consistent investment in healthcare technology by the South Korean government also supports the growth of this market, ensuring that it remains an evolving field with promising prospects for various stakeholders.

## **South Korea Anti-VEGF Market Segmentation Insights**

### **Anti-VEGF Market Product****Outlook**

### **Anti-VEGF Market Disease****Outlook**

## Market Drivers

### Increasing Aging Population

The demographic shift towards an older population in South Korea is a crucial driver for the anti vegf market. As individuals age, the prevalence of age-related ocular diseases, such as age-related macular degeneration (AMD), rises significantly. This trend is evidenced by statistics indicating that approximately 15% of individuals aged 65 and older are affected by AMD. Consequently, the demand for anti vegf therapies is expected to increase, as these treatments are essential for managing such conditions. The anti vegf market is likely to experience substantial growth, driven by the need to address the visual impairments associated with aging. Furthermore, the increasing life expectancy in South Korea, projected to reach 85 years by 2030, suggests a sustained demand for effective ocular treatments, thereby reinforcing the market's expansion prospects.

### Rising Healthcare Expenditure

The increasing healthcare expenditure in South Korea is a significant driver for the anti vegf market. With the government and private sectors investing heavily in healthcare infrastructure, the availability of advanced medical treatments is improving. In 2025, healthcare spending is projected to reach approximately $200 billion, reflecting a growth rate of around 5% annually. This increase in funding allows for better access to anti vegf therapies, which are essential for treating various ocular diseases. Furthermore, the South Korean government has been actively promoting initiatives to enhance the quality of healthcare services, which includes the reimbursement of innovative treatments. As a result, the anti vegf market is likely to benefit from this favorable financial environment, leading to increased adoption of these therapies among healthcare providers and patients alike.

### Supportive Government Policies

Supportive government policies in South Korea are playing a vital role in shaping the anti vegf market. The government has implemented various initiatives aimed at enhancing access to innovative treatments, including anti vegf therapies. These policies often include subsidies and reimbursement programs that lower the financial burden on patients. In recent years, the government has allocated approximately $50 million to support research and development in the field of ophthalmology, which is expected to yield new anti vegf products. Additionally, regulatory frameworks have been streamlined to facilitate faster approval processes for new therapies, thereby encouraging pharmaceutical companies to invest in the anti vegf market. As a result, the anti vegf market is likely to experience accelerated growth, driven by these favorable governmental actions that promote innovation and accessibility.

### Growing Awareness of Ocular Health

The rising awareness of ocular health among the South Korean population is a pivotal driver for the anti vegf market. Public health campaigns and educational initiatives have significantly increased knowledge regarding the importance of early detection and treatment of ocular diseases. As a result, more individuals are seeking regular eye examinations, leading to earlier diagnoses of conditions that require anti vegf therapies. This heightened awareness is reflected in a survey indicating that over 60% of respondents recognize the risks associated with untreated ocular diseases. Consequently, the demand for anti vegf treatments is expected to rise, as patients become more proactive in managing their eye health. The anti vegf market is likely to see a corresponding increase in treatment uptake, driven by this cultural shift towards prioritizing ocular health.

### Technological Innovations in Treatment

Technological advancements in the development of anti vegf therapies are significantly influencing the anti vegf market in South Korea. Innovations such as sustained-release formulations and novel delivery systems enhance the efficacy and convenience of treatments. For instance, recent developments in injectable therapies have shown improved patient compliance and reduced treatment frequency. The market is projected to grow at a CAGR of approximately 8% over the next five years, driven by these innovations. Additionally, the integration of digital health technologies, such as telemedicine and remote monitoring, is likely to facilitate better patient management and adherence to treatment regimens. As a result, the anti vegf market is poised for growth, as these advancements not only improve patient outcomes but also expand the accessibility of treatments across various demographics.

## Future Outlook

The [Anti VEGF Market](https://www.marketresearchfuture.com/reports/anti-vegf-market-21963) in South Korea is projected to grow at a 4.3% CAGR from 2025 to 2035, driven by increasing prevalence of retinal diseases and advancements in treatment options.

**New opportunities:**

- Development of combination therapies to enhance efficacy and patient compliance.
- Expansion of telemedicine platforms for remote patient monitoring and consultations.
- Investment in localized manufacturing to reduce costs and improve supply chain efficiency.

By 2035, the anti-VEGF market is expected to achieve substantial growth, reflecting evolving treatment paradigms.

## Segment Insights

### By Product: Eylea (Largest) vs. Beovu (Fastest-Growing)

In the South Korea anti vegf market, Eylea has established itself as the largest product by market share, significantly outpacing its competitors. Lucentis also holds a substantial share but lags behind Eylea, while Beovu is gaining traction with a smaller, yet rapidly expanding presence. This distribution highlights the dominance of Eylea, as it captures a majority of the demand driven by its proven efficacy and established brand recognition.

The growth trends in this segment reveal a shift towards newer treatments, particularly Beovu, which is identified as the fastest-growing option. Factors contributing to this trend include an increasing prevalence of retinal diseases and a rising demand for innovative therapies. Eylea continues to maintain strong performance due to its longstanding effectiveness, while Beovu's emergence showcases a response to the market's need for alternative solutions that may offer improved treatment regimens and outcomes.

Eylea (Dominant) vs. Beovu (Emerging)

Eylea serves as the dominant force in the South Korea anti vegf market, known for its robust clinical performance and widespread acceptance among healthcare professionals. This product has established itself as a first-line treatment option due to its long-lasting effects and comprehensive patient support programs. On the other hand, Beovu is emerging as a compelling alternative, attracting attention for its innovative formulation and the potential for less frequent dosing. As market dynamics evolve, Beovu’s growth is supported by positive clinical data that emphasize its efficacy, thus positioning it as a treatment option for patients seeking alternatives to traditional therapies.

### By Disease: Macular Edema (Largest) vs. Diabetic Retinopathy (Fastest-Growing)

The South Korea anti vegf market showcases distinct segments, with Macular Edema capturing the largest market share due to the rising prevalence of the condition among the aging population. This segment is closely followed by Diabetic Retinopathy, which, while currently smaller in market share, is experiencing rapid growth fueled by the increasing incidence of diabetes and associated eye conditions.

The growth trends in the market reveal a dynamic landscape, driven by advancements in treatment options and heightened awareness among healthcare professionals regarding the importance of early diagnosis. The introduction of innovative therapies is also propelling the Diabetic Retinopathy segment forward, as patients seek effective management solutions. Overall, expanded access to healthcare services contributes significantly to market growth, especially for conditions like Diabetic Retinopathy and Macular Edema.

Macular Edema (Dominant) vs. Diabetic Retinopathy (Emerging)

Macular Edema stands out as the dominant segment in the South Korea anti vegf market, largely due to its wide recognition and established treatment protocols. The condition is prominent among the aging population, and existing therapies have proven effective, reinforcing its market position. Conversely, Diabetic Retinopathy, positioned as an emerging segment, is on a growth trajectory fueled by rising diabetes rates. This segment's significance is amplified by increasing research and development efforts aimed at innovative treatment solutions. As healthcare providers focus more on preventative care, both segments are likely to benefit from enhanced therapeutic options and patient education initiatives.

## Competitive Benchmarking

The anti-VEGF market in South Korea is characterized by a dynamic competitive landscape, driven by increasing prevalence of retinal diseases and a growing aging population. Key players such as Regeneron Pharmaceuticals (US), Roche Holding AG (CH), and Novartis AG (CH) are strategically positioned to leverage innovation and expand their market presence. Regeneron Pharmaceuticals (US) focuses on enhancing its product portfolio through continuous research and development, while Roche Holding AG (CH) emphasizes strategic partnerships to bolster its therapeutic offerings. Novartis AG (CH) is actively pursuing regional expansion, particularly in Asia, to tap into emerging market opportunities. Collectively, these strategies contribute to a competitive environment that is increasingly focused on innovation and collaboration.
In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure appears moderately fragmented, with several key players exerting influence over market dynamics. This fragmentation allows for a variety of competitive strategies, as companies seek to differentiate themselves through unique product offerings and localized services.
In October 2025, Regeneron Pharmaceuticals (US) announced a collaboration with a leading South Korean research institute to develop next-generation anti-VEGF therapies. This strategic move is likely to enhance Regeneron's research capabilities and accelerate the development of innovative treatments tailored to the local market. Such collaborations may also facilitate faster regulatory approvals and market entry, positioning Regeneron favorably against its competitors.
In September 2025, Roche Holding AG (CH) launched a new digital platform aimed at improving patient engagement and adherence to anti-VEGF therapies. This initiative underscores Roche's commitment to integrating digital health solutions into its product offerings, potentially enhancing patient outcomes and solidifying its market position. By leveraging technology, Roche may gain a competitive edge in a market that increasingly values patient-centric approaches.
In August 2025, Novartis AG (CH) expanded its manufacturing capabilities in South Korea, investing approximately $50 million in a new facility dedicated to the production of anti-VEGF treatments. This expansion not only signifies Novartis's confidence in the South Korean market but also reflects a broader trend of companies investing in local production to ensure supply chain reliability and responsiveness to market demands.
As of November 2025, current trends in the anti-VEGF market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition may redefine how companies position themselves in the market, emphasizing the importance of delivering value through cutting-edge solutions.

## Recent News & Developments

The South Korea Anti-VEGF Market has shown significant activity in recent months, particularly with advancements involving prominent companies such as Regeneron Pharmaceuticals and Novartis. In September 2023, Regeneron obtained regulatory approval for its Eylea injection, aimed at treating various retinal diseases, which marks a crucial development for the regional market. In addition, Zymeworks has been expanding its pipeline, focusing on anti-VEGF therapies, which has garnered attention among local investors. Companies like Amgen and Pfizer continue to enhance their portfolios in this space, with ongoing Research and Development efforts that align with South Korea's advanced healthcare infrastructure.

Furthermore, recent months have seen considerable mergers and acquisitions, notably Santen Pharmaceutical's acquisition of a local firm to bolster its anti-VEGF portfolio in May 2023. The surge in market valuation has led to heightened competition, with Roche and AbbVie increasing their research capabilities and developing innovative strategies to capture a larger share. The consistent investment in healthcare technology by the South Korean government also supports the growth of this market, ensuring that it remains an evolving field with promising prospects for various stakeholders.

## Report Scope

| MARKET SIZE 2024 | 649.6(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 677.53(USD Million) |
| MARKET SIZE 2035 | 1032.45(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.3% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Regeneron Pharmaceuticals (US), Roche Holding AG (CH), Novartis AG (CH), Bayer AG (DE), Pfizer Inc. (US), Amgen Inc. (US), Eli Lilly and Company (US), Santen Pharmaceutical Co., Ltd. (JP) |
| Segments Covered | Product, Disease |
| Key Market Opportunities | Emerging biologics and personalized therapies drive growth in the anti vegf market. |
| Key Market Dynamics | Rising demand for innovative anti-VEGF therapies driven by increasing prevalence of retinal diseases in South Korea. |
| Countries Covered | South Korea |

## Frequently Asked Questions

**Q: What was the overall valuation of the anti-VEGF market in 2024?**
A: The overall market valuation was $649.6 Million in 2024.

**Q: What is the projected market valuation for 2035?**
A: The projected valuation for 2035 is $1,032.45 Million.

**Q: What is the expected CAGR for the anti-VEGF market during the forecast period 2025 - 2035?**
A: The expected CAGR for the market during the forecast period 2025 - 2035 is 4.3%.

**Q: Which product segment had the highest valuation in 2024?**
A: In 2024, Eylea had the highest valuation at $480.0 Million.

**Q: What is the projected valuation for the Age-Related Macular Degeneration segment by 2035?**
A: The projected valuation for the Age-Related Macular Degeneration segment by 2035 is $442.45 Million.

**Q: Which company is a key player in the anti-VEGF market?**
A: Key players in the market include Regeneron Pharmaceuticals, Roche Holding AG, and Novartis AG.

**Q: What was the valuation of the Diabetic Retinopathy segment in 2024?**
A: The valuation of the Diabetic Retinopathy segment in 2024 was $150.0 Million.

**Q: What is the projected growth for the Retinal Vein Occlusion segment by 2035?**
A: The projected growth for the Retinal Vein Occlusion segment by 2035 is to reach $190.0 Million.

**Q: How does the valuation of Beovu compare to Lucentis in 2024?**
A: In 2024, Beovu was valued at $149.6 Million, while Lucentis was valued at $350.0 Million.

**Q: What is the expected trend for the anti-VEGF market in South Korea?**
A: The anti-VEGF market in South Korea is expected to grow steadily, reaching $1,032.45 Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-anti-vegf-market-52165*